) reached 52-week high of $55.98 following the announcement of a
partnership deal with Wolters Kluwer Health, a subsidiary of
Netherlands-based global information services provider Wolters
The partnership will develop a physician documentation solution
using ProVation Clinic Note content and clinical decision
support, and Cerner Millennium health information technology
Shares closed at $55.95 at the beginning of the week. This
represented a solid one-year return of 54.5% and impressive
year-to-date return of 39.1%.
The clinical documentation solution will capture the necessary
portions of documentation for the care being provided as
physicians review results, place orders and manage the problem
list within Millennium.
ProVation Clinic Note is a product of ProVation Medical, a
division of Wolters Kluwer Health. It provides content
specifically tailored for electronic medical record (EMR)
ProVation Clinic Note helps clinicians to create evidence-based
structured physician documentation for patient encounters when
embedded in an EMR system. It delivers content across multiple
patient settings, such as ambulatory, inpatient and emergency.
Recently, Cerner expanded its HIT solution client base to 24
countries by offering Cerner Millennium to a privately-owned
674-bed Hospital Israelita Albert Einstein in Brazil. The HIT
solution will help improve the quality of patient care and
streamline operations in the hospital.
CERN started rising and has been hovering around its previous
52-week high recently following the announcement of a multiyear
partnership with Utah-based non-profit health care provider
Intermountain Healthcare, which has 22 hospitals, 185 clinics, a
medical group comprising 1,000 physicians and a health plans
The partnership agreement will implement Cerner's EMR and revenue
cycle solutions across all of Intermountain's hospitals and
clinics. It will also develop a new set of tools for a
post-fee-for-service world in areas such as activity-based
costing. It is expected to generate more than $50 million in
annual revenues for CERN.
Currently, Cerner carries a Zacks Rank #3 (Hold). While there are
no other medical information systems stocks that are currently
worth a look, we view medical product stocks such as
Bio-Rad Laboratories, Inc.
) as worth considering. All of them carry a Zacks Rank #1 (Strong
BIO-RAD LABS -A (BIO): Free Stock Analysis
CERNER CORP (CERN): Free Stock Analysis
DIADEXUS INC (DDXS): Get Free Report
RESMED INC (RMD): Free Stock Analysis Report
To read this article on Zacks.com click here.